Literature DB >> 31405818

Development of Targeted Alpha Therapy from Bench to Bedside.

Alfred Morgenstern1, Frank Bruchertseifer2.   

Abstract

This review briefly describes recent promising developments of alpha emitter labelled compounds for targeted alpha therapy of bladder cancer, brain tumours, neuroendocrine tumours, and prostate cancer.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Targeted alpha therapy; actinium-225; alpha emitter; bismuth-213; clinical application

Mesh：

Substances：

Year:  2019        PMID： 31405818     DOI： 10.1016/j.jmir.2019.06.046

Source DB:  PubMed          Journal:  J Med Imaging Radiat Sci        ISSN： 1876-7982


  3 in total

Review 1.  Targeted α-therapy in non-prostate malignancies.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-16       Impact factor: 9.236

2.  Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.

Authors:  Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 11.082

3.  Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy.

Authors:  Stefan J Roobol; Thomas A Hartjes; Johan A Slotman; Robin M de Kruijff; Guzman Torrelo; Tsion E Abraham; Frank Bruchertseifer; Alfred Morgenstern; Roland Kanaar; Dik C van Gent; Adriaan B Houtsmuller; Antonia G Denkova; Martin E van Royen; Jeroen Essers
Journal:  Nanotheranostics       Date:  2020-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.